Methyldopa injection overdosage: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
== | ==Overdosage== | ||
Acute overdosage may produce acute [[hypotension ]]with other responses attributable to brain and gastrointestinal malfunction (excessive sedation, [[weakness]], [[bradycardia]], [[dizziness]], [[lightheadedness]], [[constipation]], [[distention]], [[flatus]], [[diarrhea]], [[nausea]], [[vomiting]]). | Acute overdosage may produce acute [[hypotension ]]with other responses attributable to brain and gastrointestinal malfunction (excessive sedation, [[weakness]], [[bradycardia]], [[dizziness]], [[lightheadedness]], [[constipation]], [[distention]], [[flatus]], [[diarrhea]], [[nausea]], [[vomiting]]). | ||
Revision as of 19:45, 11 March 2014
| Methyldopa |
|---|
| Methyldopa tablet® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Methyldopa injection® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Methyldopa |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Overdosage
Acute overdosage may produce acute hypotension with other responses attributable to brain and gastrointestinal malfunction (excessive sedation, weakness, bradycardia, dizziness, lightheadedness, constipation, distention, flatus, diarrhea, nausea, vomiting).
In the event of overdosage, symptomatic and supportive measures should be employed. Management includes special attention to cardiac rate and output, blood volume, electrolyte balance, paralytic ileus, urinary function and cerebral activity.
Sympathomimetic drugs [e.g., levarterenol, epinephrine, ARAMINE* (Metaraminol Bitartrate, MSD)] may be indicated.
The acute intravenous LD50 of Methyldopate HCl in the mouse is 321 mg/kg.[1]
References
- ↑ "METHYLDOPATE HYDROCHLORIDE INJECTION, SOLUTION [AMERICAN REGENT, INC.]". Retrieved 10 March 2014.